Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | HTR7 | P34969 | 1/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | GCG | P01275 | 1/20 | 0.36 |
| ▸ | MC4R | P32245 | 1/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9652976 | 0.84 | CYP2C19 (0.47) | CYP2C19FFAR4FFAR1CYP1A2PTGS2 | |
| SCHEMBL5538023 | 0.84 | DPP4 (0.56) | FFAR4FFAR1DPP4HTR7ALDH1A1 | |
| SCHEMBL3746992 | 0.82 | CYP2C19 (0.50) | CYP2C19FFAR4FFAR1CYP1A2PTGS2 | |
| SCHEMBL3128303 | 0.82 | DPP4 (0.48) | PTGS2DPP4HTR7ALDH1A1CASP3 | |
| SCHEMBL16629574 | 0.81 | PPARA (0.46) | CYP2C19FFAR4FFAR1CYP1A2PTGS2 | |
| SCHEMBL11287161 | 0.81 | CYP2C19 (0.45) | CYP2C19FFAR4FFAR1CYP1A2PTGS2 | |
| SCHEMBL11994144 | 0.78 | PPARA (0.44) | CYP2C19FFAR4FFAR1CYP1A2PTGS2 | |
| SCHEMBL1559894 | 0.78 | CYP2C19 (0.49) | CYP2C19FFAR4FFAR1CYP1A2PTGS2 | |
| SCHEMBL1497158 | 0.78 | CYP2C19 (0.53) | CYP2C19FFAR4FFAR1CYP1A2PTGS2 | |
| SCHEMBL1610918 | 0.77 | KCNA5 (0.47) | CYP2C19CYP1A2DPP4NPC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4238334-B2 | — | — | 2009-03-18 | — | — | JP | claimed |
| US-7358265-B2 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (R&D) LTD | 2008-04-15 | — | — | US | claimed |
| EP-1476438-B1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS R&D LTD (GB) | 2007-04-18 | — | — | EP | claimed |
| EP-1754477-A2 | Hydroxamic acid derivatives as antibacterials | Vernalis (Oxford) Limited (GB) | 2007-02-21 | — | — | EP | claimed |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | VERNALIS (OXFORD) LTD (GB) | 2005-10-06 | — | — | US | claimed |
| WO-2004101537-A1 | METALLOPROTEINASE INHIBITORS | BRITISH BIOTECH PHARMACEUTICALS LTD (GB) | 2004-11-25 | — | — | WO | claimed |
| EP-1476438-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | Vernalis (Oxford) Ltd (GB) | 2004-11-17 | — | — | EP | claimed |
| US-6790834-B1 | Cytostatic agents | BRITISH BIOTECH PHARMACEUTICALS, LTD. (GB) | 2004-09-14 | — | — | US | claimed |
| WO-2003070711-A1 | OXA- AND THIADIAZOLES AND THEIR USE AS METALLOPROTEINASE INHIBITORS | VERNALIS (OXFORD) LTD (GB) | 2003-08-28 | — | — | WO | claimed |
| US-20030149084-A1 | Cytostatic agents | AYSCOUGH ANDREW PAUL (GB) | 2003-08-07 | — | — | US | claimed |
| EP-1079819-A1 | HYDROXAMIC ACID DERIVATIVES AS ANTIBACTERIALS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-03-07 | — | — | EP | claimed |
| JP-2001500149-A | — | — | 2001-01-09 | — | — | JP | claimed |
| US-6169075-B1 | ANTITUMOR AGENT INHIBITING THE PROLIFERATION OF A RANGE OF RAPIDLY DIVIDING TUMOUR CELLS LIKE MELANOMA AND/OR LYMPHOMA CELLS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2001-01-02 | — | — | US | claimed |
| EP-1054861-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-11-29 | — | — | EP | claimed |
| WO-2000043001-A1 | ANTI-INFLAMMATORY AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-07-27 | — | — | WO | claimed |
| WO-2000009119-A1 | HYDROXAMIC ACID DERIVATIVES AS INHIBITORS OF BETA-AMYLOID PRODUCTION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 2000-02-24 | — | — | WO | claimed |
| WO-1999059568-A1 | HYDROXAMIC ACID DERIVATIVES AS ANTIBACTERIALS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-11-25 | — | — | WO | claimed |
| WO-1999041232-A1 | CYTOSTATIC AGENTS | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-08-19 | — | — | WO | claimed |
| EP-0925278-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1999-06-30 | — | — | EP | claimed |
| WO-1998011063-A1 | CYTOSTATIC HYDROXAMIC ACID DERIVATIVES | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1998-03-19 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149084-A1 | Cytostatic agents | MCTS1, NNMT, MMP12 | CYP2C19 4296/4885FFAR4 1832/4885FFAR1 1718/4885 |
| US-20050222189-A1 | Oxa-and thiadiazoles and their use as metalloproteinase inhibitors | MMP9, TIMP3, MMP13 | CYP2C19 127/4885FFAR4 4860/4885FFAR1 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.